SCHEMBL1913640

SCHEMBL1913640

Cc1cc(C)c2nc(N)sc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 1.00
ALDH1A1 P00352 5/20 0.56
SMN1; SMN2 Q16637 2/20 0.52
MAPT P10636 2/20 0.52
RAB9A P51151 2/20 0.52
CYP3A4 P08684 2/20 0.50
TP53 P04637 1/20 0.50
TSHR P16473 1/20 0.50
HTT P42858 1/20 0.47
LMNA P02545 2/20 0.47
NSD1 Q96L73 2/20 0.44
GAA P10253 2/20 0.44
PDE10A Q9Y233 1/20 0.43
LCK P06239 2/20 0.41
NPC1 O15118 2/20 0.41
RORC P51449 1/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
NSD2 O96028 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21091214 0.84 HSD17B10 (0.72) HSD17B10ALDH1A1SMN1; SMN2MAPTRAB9A
SCHEMBL5247755 0.84 HSD17B10 (0.72) HSD17B10ALDH1A1SMN1; SMN2MAPTRAB9A
SCHEMBL22253414 0.81 ALDH1A1 (0.68) HSD17B10ALDH1A1SMN1; SMN2MAPTRAB9A
SCHEMBL14044812 0.81 HSD17B10 (0.68) HSD17B10ALDH1A1SMN1; SMN2MAPTRAB9A
SCHEMBL11591003 0.81 HSD17B10 (0.68) HSD17B10ALDH1A1SMN1; SMN2MAPTRAB9A
SCHEMBL21976406 0.81 HSD17B10 (0.68) HSD17B10ALDH1A1SMN1; SMN2MAPTRAB9A
SCHEMBL2271143 0.81 HSD17B10 (0.68) HSD17B10ALDH1A1SMN1; SMN2MAPTRAB9A
SCHEMBL21091494 0.81 HSD17B10 (0.68) HSD17B10ALDH1A1SMN1; SMN2MAPTRAB9A
SCHEMBL13846459 0.81 HSD17B10 (0.68) HSD17B10ALDH1A1SMN1; SMN2MAPTRAB9A
SCHEMBL5530542 0.81 HSD17B10 (0.68) HSD17B10ALDH1A1SMN1; SMN2MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0282971-B1 Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents WARNER LAMBERT CO (US) 1994-12-28 EP claimed
US-4826860-A STROKES WARNER-LAMBERT COMPANY (US) 1989-05-02 US claimed
EP-0282971-A2 Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents WARNER-LAMBERT COMPANY (US) 1988-09-21 EP claimed
US-12590071-B2 Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2026-03-31 US disclosed
US-20250382273-A1 BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS INST NAT SANTE RECH MED (FR) 2025-12-18 US disclosed
US-20250250265-A1 BENZOTHIAZOLE-PHENYLSULFONYL-PIPERIDINE ANALOGS AS ACTIVATORS OF NACYLPHOSPHATIDYLETHANOLAMINE HYDROLYZING PHOSPHOLIPASE D VANDERBILT UNIVERSITY 2025-08-07 US disclosed
EP-4460500-A1 BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM (FR) 2024-11-13 EP disclosed
CN-118660885-A Norbornene analogs and their use as potentiators of antitubercular drugs 国家医疗保健研究所 2024-09-17 CN disclosed
WO-2023201014-A1 BENZOTHIAZOLE-PHENYLSULFONYL-PIPERIDINE ANALOGS AS ACTIVATORS OF N-ACYLPHOSPHATIDYLETHANOLAMINE HYDROLYZING PHOSPHOLIPASE D VANDERBILT UNIVERSITY (US) 2023-10-19 WO disclosed
WO-2023131649-A1 BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2023-07-13 WO disclosed
US-20220396553-A1 NOVEL HYDRAZONE DERIVATIVE IN WHICH TERMINAL AMINE GROUP IS SUBSTITUTED WITH ARYL GROUP OR HETEROARYL GROUP, AND USE THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2022-12-15 US disclosed
US-4918090-A ADMINISTERING TO STROKE PATIENT WARNER-LAMBERT COMPANY (US) 1990-04-17 US disclosed
EP-0349486-A2 Azo dyes, their preparation and their use CIBA-GEIGY AG (CH) 1990-01-03 EP disclosed
US-4826860-A STROKES WARNER-LAMBERT COMPANY (US) 1989-05-02 US disclosed
EP-0282971-A2 Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents WARNER-LAMBERT COMPANY (US) 1988-09-21 EP disclosed
EP-0039818-A1 Substituted 2-(3H)-benzothiazolones, processes for their preparation, their utilization in the preparation of medicines and medicines containing them Dr. Karl Thomae GmbH (DE) 1981-11-18 EP disclosed
US-4060544-A COUPLERS GAF CORPORATION (US) 1977-11-29 US disclosed
US-4039524-A Keto-amido containing phenylazo benzothiazole dyestuffs GAF CORPORATION (US) 1977-08-02 US disclosed
US-4006127-A Cationic diazacyanine dyestuffs BAYER AKTIENGESELLSCHAFT (DT) 1977-02-01 US disclosed
US-3931145-A POLYESTER GAF CORPORATION (US) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250250265-A1 BENZOTHIAZOLE-PHENYLSULFONYL-PIPERIDINE ANALOGS AS ACTIVATORS OF NACYLPHOSPHATIDYLETHANOLAMINE HYDROLYZING PHOSPHOLIPASE D PLD1, PLD2, NAPEPLD HSD17B10 3690/4885ALDH1A1 2820/4885SMN1; SMN2 3734/4885
US-20250382273-A1 BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS BBOX1, NDUFB6, NDUFB5 HSD17B10 227/4885ALDH1A1 108/4885SMN1; SMN2 4416/4885
US-12590071-B2 Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof ABL1, TH, CYP3A43 HSD17B10 1076/4885ALDH1A1 1008/4885SMN1; SMN2 4531/4885
US-20220396553-A1 NOVEL HYDRAZONE DERIVATIVE IN WHICH TERMINAL AMINE GROUP IS SUBSTITUTED WITH ARYL GROUP OR HETEROARYL GROUP, AND USE THEREOF AANAT, NAT1, HNMT HSD17B10 313/4885ALDH1A1 402/4885SMN1; SMN2 4864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.